TScan Therapeutics, Inc 8-K, filed Oct 16, 2026
TScan Therapeutics, Inc. (TCRX)
About this 8-K
TScan Therapeutics, Inc filed this 8-K on October 16, 2026, reporting on events of October 13, 2026.
TScan Therapeutics, Inc. reported that directors Garry Nicholson and Gabriela Gruia, M.D. resigned from its Board effective October 13, 2026, with no disagreement cited, and Stephen Biggar and R. Keith Woods were appointed to the Nominating and Corporate Governance Committee. AI summary
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Resignation of Garry Nicholson and Gabriela Gruia, M.D.
On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) and each committee thereof, in each case effective as of October 13, 2026 (the “Resignations”). Neither Mr. Nicholson’s nor Dr. Gruia’s resignation was a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies. In connection with the Resignations, the Board appointed Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee (the “NCG Committee”) as member and chairperson, respectively, effective as of October 13, 2026. The NCG Committee now consists of R. Keith Woods, Katina Dorton and Stephen Biggar. The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TScan Therapeutics, Inc. | ||||||
| Date: October 16, 2026 | By: | /s/ Gavin MacBeath, Ph.D. | ||||
| Gavin MacBeath, Ph.D. Chief Executive Officer (Principal Executive Officer) | ||||||